Screener
ArriVent BioPharma, Inc. AVBP Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease liabilities | 99 | 14 |
| Total current liabilities | 24,995 | 25,945 |
| Operating lease liabilities, net of current amount | 320 | — |
| Total liabilities | 25,315 | 25,945 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Preferred stock $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock $0.0001 par value, 200,000,000 shares authorized; 45,308,941 and 42,452,251 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 5 | 4 |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s total liabilities?
- ArriVent BioPharma, Inc. (AVBP) reported total liabilities of $25.32M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s total liabilities changed year-over-year?
- ArriVent BioPharma, Inc.'s total liabilities increased by 95.4% year-over-year, from $12.95M to $25.32M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s total liabilities?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s total liabilities has grown at a 48.3% compound annual growth rate (CAGR), from $11.8M to $25.95M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about ArriVent BioPharma, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude